 | • レポートコード：MRC2209A020 • 出版社/出版日：Persistence Market Research / 2022年5月 • レポート形態：英文、PDF、141ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社発行の本調査レポートでは、世界のヒトインスリン市場について広く調査・分析し、序文、市場概要、ファイブフォース分析、産業概要、世界市場規模・予測、種類別（従来型ヒトインスリン、現代型ヒトインスリン）分析、疾患別（1型糖尿病、2型糖尿病）分析、ブランド別（従来型ヒトインスリンブランド、最新型ヒトインスリンブランド）分析、地域別分析（北米、中南米、ヨーロッパ、アジア太平洋、中東/アフリカ）、糖尿病治療薬パイプライン、競争シナリオなどの項目を掲載しております。なお、主要企業として、Novo Nordisk A/S、Eli Lilly and Company、Sanofi、Biocon、Tonghua Dongbao Pharmaceutical Co., Ltd.、ADOCIA、Wockhardt、Julphar、Merck & Co., Inc.、Pfizer, Inc.、Bristol-Myers Squibb Company、GlaxoSmithKline Plc、Oramed Pharmaceuticals, Inc.などが含まれています。 ・序文 ・市場概要 ・ファイブフォース分析 ・産業概要 ・世界市場規模・予測 ・世界のヒトインスリン市場規模：種類別 - 従来型ヒトインスリンにおける市場規模 - 現代型ヒトインスリンにおける市場規模 ・世界のヒトインスリン市場規模：疾患別 - 1型糖尿病における市場規模 - 2型糖尿病における市場規模 ・世界のヒトインスリン市場規模：ブランド別 - 従来型ヒトインスリンブランドにおける市場規模 - 最新型ヒトインスリンブランドにおける市場規模 ・世界のヒトインスリン市場規模：地域別 - 北米のヒトインスリン市場規模 - 中南米のヒトインスリン市場規模 - ヨーロッパのヒトインスリン市場規模 - アジア太平洋のヒトインスリン市場規模 - 中東/アフリカのヒトインスリン市場規模 ・糖尿病治療薬パイプライン ・競争シナリオ ・企業情報 |
Human Insulin Market Analysis 2022-2028
A recent market study published by Persistence Market Research (PMR) on the Human Insulin Market including global industry analysis for 2014-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.
Human Insulin Market: Segmentation
The global Human Insulin Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Type
Modern Human Insulin
Fast-acting
Long-acting
Premix
Traditional Human Insulin
Long-acting
Short-acting
Fast-acting
Premix
Type of Diabetes
Diabetes Type 1
Diabetes Type 2
Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa (MEA)
Key Questions Answered in Report
The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.
What are the key trends that are continuously shaping market growth?
Which are the prominent regions that offer plentiful opportunities for players in the market?
How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?
What are the differential strategies adopted by key players to hold a significant share in the human insulin industry?
Research Methodology
A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.
The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.
The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Pfizer Inc, Wockhardt, and Julpha, among others.
レポート目次1. Preface
1.1. Report Description
1.2. Research Methodology
1.3. Assumptions
2. Market Synopsis
3. Porter’s Five Forces Analysis
3.1. Bargaining Power of Suppliers
3.2. Bargaining Power of Buyers
3.3. Threat of New Entrants
3.4. Threat of Substitutes
3.5. Intensity of Rivalry
4. Industry Overview
4.1. Market Definition
4.2. Market Drivers
4.2.1. Growing prevalence of diabetes
4.2.2. Technological advancements in human insulin delivery devices
4.2.3. Increasing awareness among people towards diabetes care
4.3. Impact Analysis of Market Drivers
4.4. Market Restraints
4.4.1. Uneven pricing and limited access to human insulin in emerging countries
4.4.2. Strict regulatory requirements for drug approval
4.5. Impact Analysis of Market Restraints
4.6. Market Trends
4.6.1. Increasing usage of insulin pens for administration of human insulin
5. Global Market Size and Forecast
6. Market Size and Forecast by Type
6.1. Traditional Human Insulin
6.2. Modern Human Insulin
7. Market Size and Forecast of Traditional Human Insulin by Type
7.1. Short-acting Human Insulin
7.2. Intermediate-acting Human Insulin
7.3. Premixed Human Insulin
8. Market Size and Forecast of Modern Human Insulin by Type
8.1. Rapid-acting Human Insulin
8.2. Long-acting Human Insulin
8.3. Premixed Human Insulin
9. Market Size and Forecast by Disease
9.1. Type 1 Diabetes
9.2. Type 2 Diabetes
10. Market Size and Forecast by Brand
10.1. Traditional Human Insulin Brand
10.2. Modern Human Insulin Brand
11. Market Size and Forecast by Geography
11.1. North America
11.1.1. Scenario in the U.S.
11.1.2. Scenario in Canada
11.2. Europe
11.2.1. Scenario in Germany
11.2.2. Scenario in France
11.2.3. Scenario in the U.K.
11.3. Asia Pacific
11.3.1. Scenario in Japan
11.3.2. Scenario in China
11.3.3. Scenario in India
12. Pipeline Drugs for Diabetes Treatment
12.1. Drugs Under Development for Diabetes Treatment
13. Competitive Scenario
13.1. Competitive Benchmarking
14. Company Profiles
14.1. Novo Nordisk A/S
14.1.1. Company overview
14.1.2. Products and services
14.1.3. Financial performance
14.1.4. Key developments
14.2. Eli Lilly and Company
14.2.1. Company overview
14.2.2. Products and services
14.2.3. Financial performance
14.2.4. Key developments
14.3. Sanofi
14.3.1. Company overview
14.3.2. Products and services
14.3.3. Financial performance
14.3.4. Key developments
14.4. Biocon
14.4.1. Company overview
14.4.2. Products and services
14.4.3. Financial performance
14.4.4. Key developments
14.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
14.5.1. Company overview
14.5.2. Products and services
14.5.3. Financial performance
14.5.4. Key developments
14.6. ADOCIA
14.6.1. Company overview
14.6.2. Products and services
14.6.3. Financial performance
14.6.4. Key developments
14.7. Wockhardt
14.7.1. Company overview
14.7.2. Products and services
14.7.3. Financial performance
14.7.4. Key developments
14.8. Julphar
14.8.1. Company overview
14.8.2. Products and services
14.8.3. Financial performance
14.8.4. Key developments
14.9. Merck & Co., Inc.
14.9.1. Company overview
14.9.2. Products and services
14.9.3. Financial performance
14.9.4. Key developments
14.10. Pfizer, Inc.
14.10.1. Company overview
14.10.2. Products and services
14.10.3. Financial performance
14.10.4. Key developments
14.11. Bristol-Myers Squibb Company
14.11.1. Company overview
14.11.2. Products and services
14.11.3. Financial performance
14.11.4. Key developments
14.12. GlaxoSmithKline Plc
14.12.1. Company overview
14.12.2. Products and services
14.12.3. Financial performance
14.12.4. Key developments
14.13. Oramed Pharmaceuticals, Inc.
14.13.1. Company overview
14.13.2. Products and services
14.13.3. Financial performance
14.13.4. Key developments
TABLE 1: Market snapshot: Human insulin market, 2022 and 2028TABLE 2: Drivers for human insulin market: Impact analysis
TABLE 3: Restraints for human insulin market: Impact analysis
TABLE 4: Global human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 5: Global human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 6: Global human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 7: Global human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 8: Global traditional human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 9: Global traditional human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 10: Global modern human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 11: Global modern human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 12: Global short-acting human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 13: Global short-acting human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 14: Global intermediate-acting human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 15: Global intermediate-acting human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 16: Global premixed human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 17: Global premixed human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 18: Global rapid-acting human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 19: Global rapid-acting human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 20: Global long-acting human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 21: Global long-acting human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 22: Global premixed human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 23: Global premixed human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 24: Global type 1 diabetes human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 25: Global type 1 diabetes human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 26: Global type 2 diabetes human insulin market size, by region, 2014 – 2021 (USD million)
TABLE 27: Global type 2 diabetes human insulin market size, by region, 2022 – 2028 (USD million)
TABLE 28: Global traditional human insulin market size, by brand, 2014 – 2021 (USD million)
TABLE 29: Global traditional human insulin market size, by brand, 2022 – 2028 (USD million)
TABLE 30: Global modern human insulin market size, by brand, 2014 – 2021 (USD million)
TABLE 31: Global modern human insulin market size, by brand, 2022 – 2028 (USD million)
TABLE 32: The North American human insulin market size, by country, 2014 – 2021 (USD million)
TABLE 33: The North American human insulin market size, by country, 2022 – 2028 (USD million)
TABLE 34: The U.S. human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 35: The U.S. human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 36: The U.S. traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 37: The U.S. traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 38: The U.S. modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 39: The U.S. modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 40: The Canadian human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 41: The Canadian human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 42: The Canadian traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 43: The Canadian traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 44: The Canadian modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 45: The Canadian modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 46: The European human insulin market size, by country, 2014 – 2021 (USD million)
TABLE 47: The European human insulin market size, by country, 2022 – 2028 (USD million)
TABLE 48: The German human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 49: The German human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 50: The German traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 51: The German traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 52: The German modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 53: The German modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 54: The French human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 55: The French human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 56: The French traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 57: The French traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 58: The French modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 59: The French modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 60: The U.K. human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 61: The U.K. human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 62: The U.K. traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 63: The U.K. traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 64: The U.K. modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 65: The U.K. modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 66: The Asia Pacific human insulin market size, by country, 2014 – 2021 (USD million)
TABLE 67: The Asia Pacific human insulin market size, by country, 2022 – 2028 (USD million)
TABLE 68: The Japanese human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 69: The Japanese human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 70: The Japanese traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 71: The Japanese traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 72: The Japanese modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 73: The Japanese modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 74: The Chinese human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 75: The Chinese human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 76: The Chinese traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 77: The Chinese traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 78: The Chinese modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 79: The Chinese modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 80: The Indian human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 81: The Indian human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 82: The Indian traditional human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 83: The Indian traditional human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 84: The Indian modern human insulin market size, by type, 2014 – 2021 (USD million)
TABLE 85: The Indian modern human insulin market size, by type, 2022 – 2028 (USD million)
TABLE 86: Major pipeline drugs for diabetes treatment
TABLE 87: Major product segments of Novo Nordisk A/S
TABLE 88: Major product segments of Eli Lilly and Company
TABLE 89: Major product categories of Sanofi
TABLE 90: Major product categories of Biocon
TABLE 91: Major product categories of Tonghua Dongbao Pharmaceutical Co., Ltd.
TABLE 92: Major product categories of Adocia
TABLE 93: Major product categories of Wockhardt
TABLE 94: Major product categories of Julphar
TABLE 95: Major product categories of Merck & Co., Inc.
TABLE 96: Major product categories of Pfizer, Inc.
TABLE 97: Major product categories of Bristol-Myers Squibb Company
TABLE 98: Major product categories of GlaxoSmithKline Plc
TABLE 99: Major product categories of Oramed Pharmaceuticals, Inc.